Impact of panel design and cut-off on tumour mutational burden assessment in metastatic solid tumour samples

Tumour mutational burden (TMB) has emerged as a promising biomarker to predict immune checkpoint inhibitors (ICIs) response in advanced solid cancers. However, harmonisation of TMB reporting by targeted gene panels is lacking, especially in metastatic tumour samples. To address this issue, we used d...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Br J Cancer
Autori principali: Mankor, Joanne M., Paats, Marthe S., Groenendijk, Floris H., Roepman, Paul, Dinjens, Winand N. M., Dubbink, Hendrikus J., Sleijfer, Stefan, Cuppen, Edwin, Lolkema, Martijn P. J. K.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group UK 2020
Soggetti:
Brief Communication
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7109082/
https://ncbi.nlm.nih.gov/pubmed/32094484
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-020-0762-5
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi